New SPECT scans could spot aggressive breast cancer without biopsy
NCT ID NCT05376644
First seen Jun 29, 2026 · Last updated Jun 30, 2026 · Updated 1 time
Summary
This study tests two new radioactive imaging agents, 99mTc-ADAPT6 and 99mTc-DARPinG3, to see how well they can detect HER2-positive breast cancer using SPECT scans. Fifteen women with HER2-positive breast cancer will receive injections of each agent a few days apart, followed by imaging. The goal is to compare the imaging results with standard biopsy tests to determine if these agents can accurately identify HER2 status non-invasively before chemotherapy or targeted therapy begins.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
99mTc-ADAPT6 and 99mTc-DARPinG3
What this could lead to
If successful, these imaging agents could provide a non-invasive way to detect HER2-positive breast cancer, potentially guiding treatment decisions without needing a biopsy.
What could go wrong
This is a small, early-phase study with only 15 participants, so results may not apply to all patients. The imaging agents are experimental and their accuracy compared to standard methods is not yet proven.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HER2-POSITIVE BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Tomsk NRMC
Tomsk, 634005, Russia